Suppr超能文献

大前庭神经鞘瘤单次分割放射外科治疗的结果:系统评价和国际立体定向放射外科学会(ISRS)实践指南。

Single-fraction radiosurgery outcomes for large vestibular schwannomas in the upfront or post-surgical setting: a systematic review and International Stereotactic Radiosurgery Society (ISRS) Practice Guidelines.

机构信息

Neurosurgery Service and Gamma Knife Center, Centre Hospitalier Universitaire Vaudois (CHUV), Rue du Bugnon 44-46, BH-08, CH-1011, Lausanne, Switzerland.

Faculty of Biology and Medicine (FBM), University of Lausanne (UNIL), Lausanne, Switzerland.

出版信息

J Neurooncol. 2023 Oct;165(1):1-20. doi: 10.1007/s11060-023-04455-8. Epub 2023 Oct 16.

Abstract

PURPOSE

To perform a systematic review of literature specific to single-fraction stereotactic radiosurgery (SRS) for large vestibular schwannomas (VS), maximum diameter ≥ 2.5 cm and/or classified as Koos Grade IV, and to present consensus recommendations on behalf of the International Stereotactic Radiosurgery Society (ISRS).

METHODS

The Medline and Embase databases were used to apply the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) approach. We considered eligible prospective and retrospective studies, written in the English language, reporting treatment outcomes for large VS; SRS for large post-operative tumors were analyzed in aggregate and separately.

RESULTS

19 of the 229 studies initially identified met the final inclusion criteria. Overall crude rate of tumor control was 89% (93.7% with no prior surgery vs 87.7% with prior surgery). Rates of salvage microsurgical resection, need for shunt, and additional SRS in all series versus those with no prior surgery were 9.6% vs 3.3%, 4.7% vs 6.4% and 1% vs 0.9%, respectively. Rates of facial palsy and hearing preservation in all series versus those with no prior surgery were 1.3% vs 3.4% and 34.2% vs 40.4%, respectively.

CONCLUSIONS

Upfront SRS resulted in high rates of tumor control with acceptable rates of facial palsy and hearing preservation as compared to the results in those series including patients with prior surgery (level C evidence). Therefore, although large VS are considered classic indication for microsurgical resection, upfront SRS can be considered in selected patients and we recommend a prescribed marginal dose from 11 to 13 Gy (level C evidence).

摘要

目的

对特定于大型前庭神经鞘瘤(VS)的单次分割立体定向放射外科(SRS)的文献进行系统评价,最大直径≥2.5 厘米和/或分类为 Koos 分级 IV,并代表国际立体定向放射外科协会(ISRS)提出共识建议。

方法

使用 Medline 和 Embase 数据库应用系统评价和荟萃分析的首选报告项目(PRISMA)方法。我们考虑了符合条件的前瞻性和回顾性研究,这些研究以英语撰写,报告了大型 VS 的治疗结果;将大型术后肿瘤的 SRS 汇总分析和单独分析。

结果

最初确定的 229 项研究中有 19 项符合最终纳入标准。总体肿瘤控制的粗率为 89%(无先前手术的为 93.7%,有先前手术的为 87.7%)。所有系列与无先前手术相比,挽救性显微切除术、分流术和额外 SRS 的比率分别为 9.6%比 3.3%、4.7%比 6.4%和 1%比 0.9%。所有系列与无先前手术相比,面瘫和听力保留的比率分别为 1.3%比 3.4%和 34.2%比 40.4%。

结论

与包括先前手术患者的系列相比, upfront SRS 导致肿瘤控制率高,面瘫和听力保留率可接受(C 级证据)。因此,尽管大型 VS 被认为是显微切除术的经典适应症,但可在选定患者中考虑 upfront SRS,我们建议规定的边缘剂量为 11 至 13 Gy(C 级证据)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2434/10638172/3732cb329dfe/11060_2023_4455_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验